Journal: Cell Death & Disease

Article Title: Zebularine regulates early stages of mESC differentiation: effect on cardiac commitment

doi: 10.1038/cddis.2013.88

Figure Lengend Snippet: Characterization of HS-181 cell line after treatment with zebularine. ( a ) RT-PCR of cardiac markers after treatment with zebularine. Myh7, Myh6, Actc, cTnI and Serca2 present more expression after treatment. ( b ) Immunostaining of treated cells to detect cardiac-specific proteins. Scale bars; 50 μ m. ( c ) Blots of Proteome Profiler Array and the resulting quantification histograms demonstrating inhibition of pluripotency marker expression and ( d ) increased levels of mesodermic proteins after zebularine treatment (black arrows)

Article Snippet: Protein expression profiles were assayed using the specific human pluripotent Stem Cell array kit ‘Proteome Profiler Array' (R&D Systems Europe, Abingdon, UK; ARY010) following the manufacturer's instructions.

Techniques: Reverse Transcription Polymerase Chain Reaction, Expressing, Immunostaining, Inhibition, Marker

Journal: Molecular Medicine Reports

Article Title: A combined antitumor strategy of separately transduced mesenchymal stem cells with soluble TRAIL and IFNβ produces a synergistic activity in the reduction of lymphoma and mice survival enlargement

doi: 10.3892/mmr.2022.12722

Figure Lengend Snippet: BM-MSCs characterization. (A) BM-MSCs were adherent to the culture flask and presented elongated morphology (scale bar, 100 µm). They also expressed high mesenchymal markers, such as (B) CD90 and (C) CD105 (scale bar, 100 µm). In addition, they could differentiate to chondrogenic by (D) Alcian blue staining and calcified areas generated by osteogenic cells with (E) Von Kossa stain. BM-MSCs, bone marrow mesenchymal stem cells.

Article Snippet: MSC multipotency was examined by inducing the cells to differentiate to osteoblasts or chondroblasts, using the appropriate reagents in the Mouse Mesenchymal Stem Cell Functional Identification kit (cat. no. SC010; R&D Systems, Inc.) and following the manufacturer's instructions.

Techniques: Staining, Generated

Journal: Molecular Medicine Reports

Article Title: A combined antitumor strategy of separately transduced mesenchymal stem cells with soluble TRAIL and IFNβ produces a synergistic activity in the reduction of lymphoma and mice survival enlargement

doi: 10.3892/mmr.2022.12722

Figure Lengend Snippet: Lentiviral transduction of BM-MSC. (A-C) Lentiviral vectors were designed to contain (A) sTRAIL, (B) flTRAIL and (C) IFNβ. (D) Representative fluorescent images of BM-MSCs transduced with lentiviral vectors; nucleus stained with DAPI (blue) and transduced BM-MSCs expressing GFP protein (green signal). (E and F) Western blot analysis confirming protein expression of (E) flTRAIL and sTRAIL (F) and IFNβ in untransfected MSCs and MSCs transduced with a lentivirus that does not contain any of the genes of interest (empty lentiviral vector pLV[Exp]-EGFP:T2A:Puro-EF1A> mCherry, Vector Builder). MSCs express each of the genes flTRAIL, sTRAIL and IFN and as positive control the recombinant protein. Actin was used as a loading control. BM-MSCs, bone marrow mesenchymal stem cells; sTRAIL, TRAIL soluble; flTRAIL, TRAIL full length; IFNβ, interferon β.

Article Snippet: MSC multipotency was examined by inducing the cells to differentiate to osteoblasts or chondroblasts, using the appropriate reagents in the Mouse Mesenchymal Stem Cell Functional Identification kit (cat. no. SC010; R&D Systems, Inc.) and following the manufacturer's instructions.

Techniques: Transduction, Staining, Expressing, Western Blot, Plasmid Preparation, Positive Control, Recombinant, Control

Journal: Molecular Medicine Reports

Article Title: A combined antitumor strategy of separately transduced mesenchymal stem cells with soluble TRAIL and IFNβ produces a synergistic activity in the reduction of lymphoma and mice survival enlargement

doi: 10.3892/mmr.2022.12722

Figure Lengend Snippet: Kaplan-Meier curves. (A) First model with all treatments. (B) Second model with sTRAIL and IFNβ treatment and MSC naïve. *P<0.05 and **P<0.001 compared with the untreated group. sTRAIL, TRAIL soluble; IFNβ, interferon β; MSC, mesenchymal stem cell.

Article Snippet: MSC multipotency was examined by inducing the cells to differentiate to osteoblasts or chondroblasts, using the appropriate reagents in the Mouse Mesenchymal Stem Cell Functional Identification kit (cat. no. SC010; R&D Systems, Inc.) and following the manufacturer's instructions.

Techniques: